Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 1

Status

Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Advanced Solid Tumors 432Advanced Solid Tumor 352Solid Tumor 305Solid Tumors 246Mesothelioma 115Solid Tumor, Adult 76Mesothelioma, Malignant 72Carcinoma, Non-Small-Cell Lung 66Ovarian Neoplasms 47Melanoma 42Carcinoma, Renal Cell 37Colorectal Neoplasms 34Advanced or Metastatic Solid Tumors 32Uterine Cervical Neoplasms 31Stomach Neoplasms 31Solid Tumours 31Esophageal Neoplasms 30Neoplasms 27Pancreatic Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Advanced Malignant Solid Tumors 25Triple Negative Breast Neoplasms 24Lung Neoplasms 24Small Cell Lung Carcinoma 23Advanced Solid Tumours 23Sarcoma 21Neoplasm Metastasis 21Advanced Malignant Solid Tumor 21Locally Advanced or Metastatic Solid Tumors 20

Interventions

tebentafusp 1pembrolizumab 1atezolizumab 1Drug Therapy 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Select Advanced Solid Tumors × Other solid neoplasm × Clear all
NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Immunocore Ltd

Phase 1/2 Active not recruiting
410 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

NCT06402201 2026-02-27

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

CDR-Life AG

Phase 1 Recruiting
42 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Immunocore Ltd

Phase 1/2 Withdrawn
Other solid neoplasm

Select Advanced Solid Tumors

NCT03515551 2022-03-11

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Immunocore Ltd

Phase 1/2 Terminated
29 enrolled 25 charts
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡